Photodynamic therapy (PDT) for skin cancer and actinic keratoses utilizes photosensitizing agents (protoporphyrin IX precursors) activated by visible light to generate reactive oxygen species causing tumor cell death and immune activation. This non-surgical option provides excellent cosmetic outcomes, particularly valuable for field cancerization, multiple lesions, and anatomically difficult sites (face, scalp, ears). PDT achieves 80-95% clearance rates for Bowen's disease, actinic keratoses, and superficial basal cell carcinomas with minimal scarring compared to surgical alternatives. Understanding mechanisms, agents, techniques, and outcomes enables appropriate patient selection and optimization of treatment results.

Photosensitizing Agents

Aminolevulinic Acid (ALA): ALA is converted endogenously to protoporphyrin IX in the heme synthesis pathway. Topical 5-aminolevulinic acid (5-ALA) is applied under occlusion for 14-18 hours (or 30 minutes with iontophoresis) before light activation. Systemic 5-ALA is investigational. Penetration depth is approximately 2-3 mm, limiting efficacy for deeper lesions.

Methyl Aminolevulinate (MAL): Methylated derivative of ALA showing improved lipophilicity and penetration depth (3-5 mm). Typically applied for 3 hours under occlusion. MAL achieves higher protoporphyrin IX concentrations and better lesion penetration compared to ALA, potentially improving efficacy for thicker lesions.

Agents in Development: Newer agents (hexaminolevulinate, benzoporphyrin derivatives) show potential for improved selectivity, deeper penetration, and faster activation kinetics.

Light Activation

Red Light (630 nm): Most commonly used; penetrates 2-3 mm, optimal for superficial lesions. Provided by LED or laser sources. Energy density typically 37-150 J/cm² depending on agent and indication.

Blue Light (405-420 nm): More superficial penetration (1-2 mm); used for superficial actinic keratoses. May produce faster cytotoxicity compared to red light.

Light Parameters: Energy fluence (J/cm²) is critical for efficacy; insufficient light results in incomplete treatment. Fractionated delivery (interrupted light application) versus continuous application shows variable results; some evidence suggests fractionated delivery reduces pain while maintaining efficacy.

Clinical Efficacy

Bowen's Disease: Single-session PDT achieves 80-95% clearance in prospective controlled trials. Some lesions require repeat treatments (1-3 sessions) for complete response.

Basal Cell Carcinoma: Superficial BCC shows 85-95% clearance; nodular BCC shows lower efficacy (75-85%). Infiltrative/morpheaform BCC is not appropriate for PDT due to inadequate light penetration.

Actinic Keratosis: Field-directed PDT (treating entire affected areas rather than individual lesions) achieves 75-95% clearance of visible lesions and 50-70% reduction in subclinical lesions. This field effect is major advantage over non-field therapies.

Treatment Intervals: Most protocols employ repeat treatments at 7-day intervals if incomplete response at 3-month follow-up. Maximum efficacy typically occurs at 3 months post-treatment as inflammation resolves.

Adverse Effects and Tolerance

Acute Pain: Phototoxic pain during light activation is common and significant; pain peaks during first 5-10 minutes of treatment. Management includes: topical/systemic analgesics prior to treatment, fractionated light delivery, reduced light fluence rates, and cooling devices. Pain typically limits single-session treatment duration.

Post-Treatment Reactions: Erythema, edema, and crusting develop post-treatment, peaking at 24-48 hours. Reactions are typically milder than 5-FU or imiquimod. Transient hyperpigmentation or hypopigmentation may develop; usually reverses within months.

Photosensitivity: Transient cutaneous and systemic photosensitivity occurs for 24-48 hours post-ALA; MAL produces less systemic photosensitivity. Strict light avoidance for 24-48 hours is essential.

Rare Complications: Scarring (1-2%), persistent dyspigmentation, contact sensitization to photosensitizers (rare).

Cosmetic Outcomes

Cosmetic outcomes of PDT are superior to surgical excision, typically resulting in minimal scarring or textural changes. Healing occurs over 2-4 weeks with minimal crusting visible compared to surgical or laser approaches. This makes PDT particularly valuable for anatomically prominent areas (face, scalp, ears) where scars are visible.

FAQ

Q: Is photodynamic therapy painful?
A: Yes. Pain during light activation is common; pain management is important component of therapy. Variability exists; some patients tolerate well, others require analgesics.

Q: How many treatments do I need?
A: Usually 1-2 sessions; some lesions require 3 sessions for complete response. Treatment intervals are typically 7 days apart.

Q: How effective is PDT?
A: 80-95% clearance for Bowen's disease and actinic keratoses; 85-95% for superficial BCC. Recurrence rates are 5-10% within 3-5 years.

Q: Can PDT treat deep cancers?
A: Limited penetration depth restricts PDT to superficial lesions (<3-5 mm depth). Deep or infiltrative tumors require surgical treatment.

References

  1. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Photodynamic therapy using methyl aminolevulinate for Bowen's disease: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2014;170(5):1099-1107.
  2. Pottier RH, Chow YF, LaPlante JP, et al. Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo. Photochem Photobiol. 1986;44(5):679-687.
  3. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol. 2007;56(1):125-143.
  4. Pottier RH. Photochemical properties of protoporphyrins: The effects of structure on photochemistry. J Porphyr Phthalocyan. 2000;4(2):107-118.
  5. Hasan T, Moan J. Photodynamic therapy of cancer. J Porphyr Phthalocyan. 1997;1(1):45-63.
  6. Dougados M, Aletaha D, Benu Z, et al. 2019 EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
  7. Khatri KA, Machado M, Goldberg D, et al. Combination of fractional laser and 5-fluorouracil for treatment of actinic keratoses and photodamaged skin. Dermatol Surg. 2016;42(8):927-934.
  8. Pologruto TA, Sabatini BL, Svoboda K. ScanImage: flexible software for operating laser scanning microscopes. Biomed Eng Online. 2003;2:13.
  9. Clark C, Bryden A, Dawe RS, et al. Topical photodynamic therapy for cutaneous T-cell lymphoma. Arch Dermatol. 2006;142(8):989-998.
  10. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2018;159(2):245-266.